Top Page
CANbridge Pharmaceuticals Inc.
(1228)
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
CANbridge Pharmaceuticals Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.56M | 85.10M | 102.87M | 78.97M | 31.16M | 12.03M |
| Gross Profit | 40.29M | 54.30M | 64.16M | 48.89M | 18.78M | 6.88M |
| EBITDA | -150.16M | -328.69M | -341.43M | -454.63M | -1.06B | -824.41M |
| Net Income | -136.11M | -442.62M | -378.84M | -483.48M | -1.08B | -846.04M |
Balance Sheet | ||||||
| Total Assets | 105.50M | 116.81M | 395.36M | 702.04M | 892.52M | 586.36M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 10.50M | 137.49M | 451.16M | 745.82M | 360.80M |
| Total Debt | 34.97M | 135.78M | 141.93M | 155.28M | 52.10M | 46.90M |
| Total Liabilities | 514.58M | 591.30M | 435.15M | 393.49M | 199.13M | 2.33B |
| Stockholders Equity | -409.08M | -474.49M | -39.79M | 308.56M | 693.39M | -1.75B |
Cash Flow | ||||||
| Free Cash Flow | -14.19M | -122.50M | -319.09M | -315.76M | -592.40M | -305.13M |
| Operating Cash Flow | -14.10M | -122.39M | -278.23M | -280.98M | -587.07M | -151.65M |
| Investing Cash Flow | -38.00K | 13.93M | -26.86M | -34.79M | 126.09M | -153.48M |
| Financing Cash Flow | 0.00 | -18.57M | -28.02M | -20.70M | 854.31M | 679.26M |
CANbridge Pharmaceuticals Inc. Technical Analysis
CANbridge Pharmaceuticals Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$2.67B | -2.57 | ― | ― | 79.98% | -3.40% | |
| ― | HK$1.05B | ― | ― | ― | ― | 83.89% | |
| ― | HK$939.92M | -5.27 | ― | ― | -40.24% | 66.43% | |
| ― | HK$1.35B | -4.32 | -34.18% | ― | -57.84% | 24.58% | |
| ― | HK$1.57B | ― | -51.56% | ― | 2.45% | 2.58% | |
| ― | HK$921.92M | ― | -54.87% | ― | ― | 81.67% |
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge Pharmaceuticals Inc. has successfully completed the subscription of new shares under a general mandate, issuing nearly 10 million shares at a price of HK$2.26 each, generating gross proceeds of approximately HK$22.59 million. This strategic move, involving independent subscribers, is expected to bolster the company’s financial position and support its operational plans, enhancing its market presence and potentially benefiting stakeholders by expanding its capital base.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
CANbridge Pharmaceuticals Inc. has entered into three subscription agreements to issue nearly 10 million new shares at a discounted price of HK$2.26 each, raising gross proceeds of approximately HK$22.59 million. The net proceeds will be used for research and development of existing products and daily operations, potentially strengthening the company’s financial position and enhancing its ability to innovate in the biopharmaceutical industry.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
CANbridge Pharmaceuticals Inc. has announced additional details regarding the write-off of its right of use assets related to its office and laboratory in Boston, U.S., as part of its downsizing efforts. The lease liabilities remained recognized in the financial statements as of December 31, 2024, due to the lease contract’s legal binding until February 28, 2025. Additionally, the company provided updates on its share schemes, detailing the exercise of options and vesting of RSUs under its Pre-IPO Equity Incentive Plan and Post-IPO RSU Scheme, reflecting ongoing employee incentives and stock management strategies.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
CANbridge Pharmaceuticals Inc. announced significant progress in its drug pipeline and business operations for the first half of 2025. The company has entered a strategic cooperation with Baheal Medical, enhancing its marketing and distribution capabilities in China, Hong Kong, and Macau. Key product developments include the commercial launch and expanded insurance coverage for Hunterase® and Livmarli®, as well as the marketing approval for Gaurunning®, a new drug for Gaucher Disease. Additionally, CANbridge is advancing its gene therapy program for Duchenne Muscular Dystrophy, having licensed new technology and generated pre-clinical proof-of-concept data.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
CANbridge Pharmaceuticals Inc. has completed the subscription of new shares under a general mandate, raising gross proceeds of HKD100,461,767.12. This financial move is part of a strategic cooperation agreement with Baheal Zhihe, which will act as the exclusive marketing service provider for CANbridge’s products in designated regions. Additionally, the company has appointed Mr. Wang Tingwei as a non-executive director and a member of the Nomination Committee, further strengthening its corporate governance structure.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
CANbridge Pharmaceuticals Inc. has announced that its Board of Directors will convene on August 29, 2025, to review and approve the company’s unaudited interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial health and operational progress, potentially impacting investor confidence and stakeholder engagement.
CANbridge Pharmaceuticals Inc. has entered into a strategic collaboration and exclusive commercial services agreement with a subsidiary of Qingdao Baheal Medical Inc. This agreement appoints Baheal as the exclusive Contract Sales Organization for promoting CANbridge’s products in mainland China, Hong Kong, and Macau. The agreement, which is of a revenue nature and part of the company’s ordinary business activities, does not constitute a notifiable or connected transaction under Hong Kong’s listing rules. This strategic move is expected to enhance CANbridge’s market presence in the Greater China region.
CANbridge Pharmaceuticals Inc. has entered into a Subscription Agreement to issue 74,971,468 new shares at a price of HK$1.34 per share, representing a discount to the last trading day’s closing price but a premium to the average closing price over the past five days. The gross proceeds from this subscription are expected to be over HK$100 million, with net proceeds earmarked for research and development, marketing, loan repayment, and daily operations. The subscription is subject to approval from the Stock Exchange, and trading of the company’s shares was temporarily halted pending this announcement.
CANbridge Pharmaceuticals Inc. has announced a trading halt on its shares on the Hong Kong Stock Exchange, effective from August 12, 2025. This halt is pending the release of an announcement containing inside information, which may have significant implications for the company’s operations and its stakeholders.